Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

Biologics, Inc., the leading cancer management company in the United States, announces that its Oncology Clinical Trial Services division has been selected by the National Marrow Donor Program® (NMDP), a nonprofit organization that facilitates unrelated hematopoietic cell transplants.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

12 Feb 2010

MacSpeech Scribe Medical add-on component released

MacSpeech, Inc. today announced MacSpeech Scribe Medical, an add-on component that incorporates the world's most advanced personal transcription for the Macintosh with MacSpeech Dictate Medical, the medical professional's speech recognition solution for the Macintosh.

12 Feb 2010

Fourth-quarter and full-year 2009 results announced by Quidel

Quidel Corporation, a leading provider of rapid point-of-care diagnostic tests, announced today financial results for the fourth quarter and full year ended December 31, 2009.

12 Feb 2010

RadPharm and Medifacts International announce merger

RadPharm Inc., a leading Imaging Core Laboratory, and Medifacts International, Inc., a leading Cardiovascular Core Laboratory, today announced the merger of their business operations. The combined company will be named CoreLab Partners ("CoreLabs") and will have its corporate headquarters in Princeton, New Jersey.

11 Feb 2010

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008.

11 Feb 2010

Lack of provider status denies radiation oncologists authority to make decisions based on patient safety and treatment accuracy

Our members deeply regret the needless tragedies outlined in the Times articles and express our sympathy to the families who have lost loved ones and witnessed their suffering. Our hearts also go out to all others whose lives have been impacted by these tragedies including therapists, physicians and physicists. We feel that, as radiation oncology professionals, we are all, directly or indirectly, responsible for these disastrous treatment errors and we therefore must, in future, take a more active role to assure episodes like these are never repeated.

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

PAREXEL International, Proteome Sciences form biomarker alliance

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and Proteome Sciences plc, a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of an alliance focused on enhancing PAREXEL's biomarker capabilities for early phase clinical development. PAREXEL is using Proteome Sciences' PS Biomarker Services™ protein and peptide biomarker capabilities to support biopharmaceutical companies in making earlier assessments of new compounds in development.

From Parexel 11 Feb 2010

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.

11 Feb 2010

Bard FLAIR Endovascular Stent Graft more effective than balloon angioplasty for failing dialysis grafts

C. R. Bard, Inc. today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone. The FLAIR® Endovascular Stent Graft is the only implant approved by the U.S. Food and Drug Administration for use in the treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous access grafts.

11 Feb 2010

Research study on epigenetic phenotypes published online in the Journal of Clinical Oncology

PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.

11 Feb 2010

'CARES by GSK' introduces oncology co-pay assistance program

GlaxoSmithKline today announced the launch of CARES by GSK, a comprehensive program that provides a single point of contact to GSK services and programs designed to improve access to GSK oncology and specialty medications. In addition to the comprehensive offerings that include specialty reimbursement services and free medicine, CARES by GSK now offers its first oncology co-pay assistance program to further help eligible patients with limited insurance coverage to have better access to GSK oral oncology and specialty medicines.

11 Feb 2010

Role of evidence-based pathways in providing high quality, cost effective oncology care

Although health care reform is taking a back seat to the economy on Capitol Hill, discussions continue in the health care industry on how best to lower the cost of care while maintaining or improving patient outcomes.

11 Feb 2010

Allos Therapeutics' disease-specific registry for patients with PTCL enrolls first study participant

MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, is pleased to announce that Allos Therapeutics' new international disease-specific registry for patients with peripheral T-cell lymphoma (PTCL) has enrolled its first study participant.

11 Feb 2010

ASO announces additional society affiliation with the American Society of Breast Surgeons

The Annals of Surgical Oncology (ASO), the official journal of the Society of Surgical Oncology, has announced an additional society affiliation with the American Society of Breast Surgeons beginning in 2010. Published by Springer, the ASO is a leading monthly publication that features original articles on the latest advances in oncology for surgeons from all specialties.

11 Feb 2010

CTI reports financial results for fourth-quarter and year ended December 31, 2009

Cell Therapeutics, Inc. (CTI) today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2009.

11 Feb 2010

Hospira's proposed generic injectables business acquisition: HSR review period expires

Hospira, Inc.,, the world leader in generic injectable pharmaceuticals, and Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, today announced that the Hart-Scott-Rodino (HSR) review period for Hospira's proposed acquisition of Orchid's generic injectable pharmaceuticals business has expired with no action by the Federal Trade Commission (FTC).

11 Feb 2010

Micromet outlines the design of registration study for blinatumomab in ALL

At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.

11 Feb 2010

Oncology News and Research

Further Reading

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

Second-quarter fiscal 2010 results announced by Pharmacyclics

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

MacSpeech Scribe Medical add-on component released

Fourth-quarter and full-year 2009 results announced by Quidel

RadPharm and Medifacts International announce merger

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Lack of provider status denies radiation oncologists authority to make decisions based on patient safety and treatment accuracy

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

PAREXEL International, Proteome Sciences form biomarker alliance

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

Bard FLAIR Endovascular Stent Graft more effective than balloon angioplasty for failing dialysis grafts

Research study on epigenetic phenotypes published online in the Journal of Clinical Oncology

'CARES by GSK' introduces oncology co-pay assistance program

Role of evidence-based pathways in providing high quality, cost effective oncology care

Allos Therapeutics' disease-specific registry for patients with PTCL enrolls first study participant

ASO announces additional society affiliation with the American Society of Breast Surgeons

CTI reports financial results for fourth-quarter and year ended December 31, 2009

Hospira's proposed generic injectables business acquisition: HSR review period expires

Micromet outlines the design of registration study for blinatumomab in ALL

A best-practice guide for laboratory services in oncology trials eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News